— Know what they know.
Not Investment Advice
Also trades as: 0R1B.L (LSE) · $vol 0M · IDP.DE (XETRA) · $vol 0M · BIIB.SW (SIX)

BIIB NASDAQ

Biogen Inc.
1W: +4.0% 1M: +10.5% 3M: +20.8% YTD: +42.1% 1Y: +68.6% 3Y: -1.8% 5Y: -5.7%
$252.73
+0.47 (+0.19%)
 
Weekly Expected Move ±4.4%
$229 $240 $251 $262 $273
NASDAQ · Healthcare · Drug Manufacturers - General · Tech Score Strong Buy · Power 71 · $37.3B mcap · 147M float · 0.788% daily turnover · Short 70% of daily vol
Credit Risk of going bust: lower than 68% of companies Debt: 18.3% of company value Bonds: $137.0M held by 192 funds, 91 bp over Treasuries → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $4.22 (down 98%), Biogen Inc. would be worth roughly what it owes.
Total debt $8.36B against a stock market value of $37.27B.
Distance to default 7.34 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $4.45B (short-term plus half of long-term), stock volatility 33.9%; Altman Z 3.16. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.

Balance Sheet Trends

Total Assets
$29.4B +5.0% ▲
5Y CAGR: +3.6%
Total Liabilities
$11.2B -1.3% ▼
5Y CAGR: -4.3%
Shareholders Equity
$18.3B +9.2% ▲
5Y CAGR: +11.3%
Cash & Investments
$3.8B +60.7% ▲
5Y CAGR: +7.9%
Total Debt
$6.9B +4.8% ▲
5Y CAGR: -2.4%
Net Debt
$3.9B -7.4% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$2.3B$3.4B$1.0B$2.4B$3.0B
Short-Term Investments$1.5B$1.5B$0$0$807M
Cash & ST Investments$3.8B$4.9B$1.0B$2.4B$3.8B
Net Receivables$2.0B$2.1B$2.1B$1.9B$1.9B
Inventory$1.4B$1.3B$2.5B$2.5B$2.2B
Other Current Assets$741M$1.4B$1.2B$752M$1.1B
Total Current Assets$7.9B$9.8B$6.9B$7.5B$9.0B
Property, Plant & Equip.$3.8B$3.7B$3.7B$3.5B$3.3B
Goodwill & Intangibles$8.0B$7.6B$14.6B$16.2B$15.7B
Long-Term Investments$892M$706M$0$227M$751M
Other Non-Current Assets$1.9B$1.5B$745M$334M$432M
Total Non-Current Assets$16.0B$14.8B$20.0B$20.6B$20.5B
Total Assets$23.9B$24.6B$26.8B$28.0B$29.4B
— Liabilities —
Accounts Payable$589M$492M$403M$424M$432M
Short-Term Debt$999M$0$150M$1.7B$80M
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$345M$1.1B$335M$376M$2.7B
Total Current Liabilities$4.3B$3.3B$3.4B$5.5B$3.3B
Long-Term Debt$6.3B$6.3B$6.8B$4.5B$6.6B
Other Non-Current Liab.$1.3B$944M$781M$732M$458M
Total Non-Current Liabilities$8.6B$7.9B$8.6B$5.8B$7.8B
Total Liabilities$12.9B$11.2B$12.0B$11.3B$11.2B
— Equity —
Common Stock$100K$100K$100K$100K$100K
Retained Earnings$13.9B$16.5B$17.6B$19.3B$20.6B
Accumulated OCI-$107M-$165M-$154M-$136M-$182M
Total Stockholders Equity$10.9B$13.4B$14.8B$16.7B$18.3B
Total Liabilities & Equity$23.9B$24.6B$26.8B$28.0B$29.4B
— Key Metrics —
Total Debt$7.6B$6.6B$7.3B$6.6B$6.9B
Net Debt$5.3B$3.2B$6.3B$4.3B$3.9B
Total Investments$2.4B$2.2B$0$227M$1.6B

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms